Thu Aug 30, 2012 11:29am EDT (Reuters) – Shares of Sarepta Therapeutics Inc rose as much as 20 percent to a 19-month high on Thursday after a Missouri TV station said the company’s experimental drug for muscle weakness and loss of muscle tissue showed positive signs in one of the 12 enrolled patients. The drug Eteplirsen is being tested in a mid-stage trial to treat patients with Duchenne Muscular Dystrophy (DMD), a genetic disorder that causes severe and progressive muscle loss in boys and has no approved treatments.

[Continue Reading...]